B cell count tells how certain cancers will respond to immunotherapy

B cell count tells how certain cancers will respond to immunotherapy

B cell count tells how certain cancers will respond to immunotherapy

Some melanomas, sarcomas and renal cell carcinomas, but not all, have been found to respond dramatically to new drugs called immune checkpoint blockers, which exploit the body’s known capability to mount an immune response against the foreign antigen-bearing tumor cells.